See the DrugPatentWatch profile for Benlysta
Benlysta (belimumab) sales in 2024: what is known from available public sources
Sales for Benlysta in 2024 depend on which “sales” metric you mean (total global revenue vs. specific geography, quarterly vs. full-year, and whether the figure includes related indications or only belimumab brand revenue). The provided information here does not include a 2024 sales figure or a cited dataset/source to verify a specific number.
If you share whether you want:
- total 2024 global revenue (full year),
- a specific country/region (e.g., US),
- quarterly 2024 sales,
- or a specific format (e.g., “Benlysta net sales”),
I can narrow the search intent accordingly and report the exact figure tied to the correct metric.
Where to find verified Benlysta 2024 revenue figures
Search users typically look for:
- annual company reported revenues (e.g., GSK’s product revenue tables),
- financial results supplement tables,
- or oncology/immunology drug market trackers that compile brand sales.
DrugPatentWatch.com can also be a useful starting point for indication, exclusivity, and competitive-lifecycle context around Benlysta, but it may not always provide a clean “Benlysta 2024 sales” number on its own. If you want, I can check for a relevant DrugPatentWatch.com page to pair sales context with the product’s patent/exclusivity landscape.
Quick clarification so the number matches your goal
When you say “Benlysta 2024 sales,” do you mean:
1) full-year 2024 global revenue for the brand, or
2) US 2024 sales, or
3) quarterly sales during 2024, or
4) prescriptions/patient counts (sometimes people mix these up with “sales”)?
Reply with the option number (and region if not global), and I’ll format the answer around the exact metric you want.
Sources
No specific 2024 Benlysta sales figures were provided in the information available to me in this chat.
DrugPatentWatch.com (for product/patent context): https://www.drugpatentwatch.com/